Novikov D K, Borisenko I D, Shein I A
Vopr Onkol. 1978;24(12):50-5.
The reaction of leucocyte migration inhibition (RLMI), using antigens of autochthonous and allogenic tumors, was utilized to examine 21 patients with renal cancer and in 37 control patients. The antigens of renal cancer (AG RC) would suppress specifically leucocyte migration in all patients with cancer of the kidney, as compared with the migration without antigens or in the presence of normal tissue antigens of the tumor involved kidney. In 5 of 37 cases AG RC as well as those of normal renal tissue inhibited leucocyte migration in patients with urolithiasis and pyelonephritis. Autologous blood plasma in patients with renal cancer would contribute to inhibition of leucocyte migration by cancer antigens. There are some common specific antigens in renal cancer, recognized by lymphocytes from different patients with the tumor in question. RLMI may be used to establish the immune diagnosis of cancer of the kidney.
利用自体肿瘤抗原和同种异体肿瘤抗原的白细胞迁移抑制反应(RLMI),对21例肾癌患者和37例对照患者进行了检测。与无抗原或存在患肾正常组织抗原时的迁移情况相比,肾癌抗原(AG RC)能特异性抑制所有肾癌患者的白细胞迁移。在37例病例中的5例,AG RC以及正常肾组织抗原抑制了尿路结石和肾盂肾炎患者的白细胞迁移。肾癌患者的自体血浆会促进癌抗原对白细胞迁移的抑制作用。肾癌中存在一些共同的特异性抗原,可被不同肾癌患者的淋巴细胞识别。RLMI可用于肾癌的免疫诊断。